This open-label study will assess the long-term efficacy, safety, and tolerability of onabotulinumtoxinA administered for prophylaxis of headaches in patients with chronic migraine.
Inclusion Criteria:
Exclusion Criteria:
Jongno-Gu, Seoul, South Korea
Jongno-Gu, Seoul, South Korea
Nowon-Gu, Seoul, South Korea
Seodaemum-Gu, Seoul, South Korea